05:10 PM EDT, 09/12/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said late Thursday that a phase 2 clinical trial of experimental compound luvadaxistat didn't meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.

"It failed to replicate the cognitive endpoints data seen in the earlier Interact study, due in part to the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms," the company said.

Neurocrine plans to halt further development of luvadaxistat and focus on the advancement into phase 3 clinical development of NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder, Chief Medical Officer Eiry Roberts said.

The company's shares were down about 1% in after-hours activity.

Price: 120.00, Change: -1.28, Percent Change: -1.06